Goldman Sachs raised Agios (AGIO.US) target price to $28, bullish on the prospect of the new drug Aqvesme for Mediterranean anemia.

According to the Wisdom Financial APP, Goldman Sachs has raised the 12-month target price of Agios Pharmaceuticals (AGIO.US) from $25 to $28, representing a potential increase of about 14%, while maintaining a "neutral" rating. The analysis by the bank on Agios Pharmaceuticals focuses on the market prospects and risk assessment of its core drug Aqvesme (mitapivat) after FDA approval.